https://scholars.lib.ntu.edu.tw/handle/123456789/596348
標題: | Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91 | 作者: | Yeh T.-K. Li C.-M. Chen C.-P. Chuu J.-J. Huang C.-L. Wang H.-S. Shen C.-C. Lee T.-Y. Chang C.-Y. Chang C.-M. Chao Y.-S. CHIN-TARNG LIN Chang J.-Y. Chen C.-T. |
關鍵字: | Anticancer activity; Camptothecin; DB-67; Lactone stability; Pharmacokinetics; Topoisomerase I | 公開日期: | 2010 | 卷: | 61 | 期: | 2 | 起(迄)頁: | 108-115 | 來源出版物: | Pharmacological Research | 摘要: | DB-67 and its lactone homolog DB-91 are derivatives of topoisomerase I inhibitor camptothecin (CPT) with silyl moiety, which may exhibit a slower inactivation process by changed kinetics of protein binding and/or hydrolysis of its lactone ring and result in increased antitumor activity and decreased toxicity. Pharmacokinetic properties and antitumor activities of the two silatecans were studied and compared. The lactone ring of DB-91 is more stable than those of all the other CPT derivatives in mouse plasma. Both silatecans were metabolized faster than CPT in mouse and human liver microsomes. Pharmacokinetic study revealed a plasma elimination half-life (t1/2) of 33 and 94 min for DB-67 and DB-91, respectively; similar systemic exposure in plasma between DB-67 and DB-91; and similar volume of distribution at the steady state between DB-67 and DB-91, approximately 15-fold smaller than that of CPT. While DB-91 showed limited activities, DB-67 exhibited activities against the growth of in vivo-like histocultured human tumors and s.c. xenografted human tumors in nude mice. In conclusion, DB-67 is more effective, compared to DB-91, against human tumor growth in in vitro, in vivo-like and in vivo systems. Further pre-clinical and clinical investigations of DB-67 are warranted. ? 2009 Elsevier Ltd. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-73949141120&doi=10.1016%2fj.phrs.2009.07.005&partnerID=40&md5=9cdfb0b7b6f642f25d4291a49f260fc3 https://scholars.lib.ntu.edu.tw/handle/123456789/596348 |
ISSN: | 1043-6618 | DOI: | 10.1016/j.phrs.2009.07.005 | SDG/關鍵字: | camptothecin; camptothecin derivative; db 67; db 91; DNA topoisomerase; DNA topoisomerase inhibitor; lactone; silatecan derivative; unclassified drug; animal cell; animal experiment; animal model; animal tissue; antineoplastic activity; article; bolus injection; cancer inhibition; clinical effectiveness; controlled study; drug distribution; drug efficacy; drug elimination; drug half life; drug metabolism; drug stability; drug structure; human; human cell; in vitro study; in vivo study; liver microsome; male; malignant neoplastic disease; mouse; nonhuman; nude mouse; priority journal; steady state; structure activity relation; tumor xenograft; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; DNA Topoisomerases, Type I, Eukaryotic; Drug Resistance, Neoplasm; Drug Stability; Enzyme Inhibitors; Female; Half-Life; Humans; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microsomes, Liver; Neoplasms; Organosilicon Compounds; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。